Amalgamated Financial’s Kyntra Bio KYNB Stock Holding History

Amalgamated Financial’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$165K	Buy	+549	New	+$191K	﹤0.01%	1971

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Amalgamated Financial's KYNB Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Kyntra Bio (KYNB) in Q1 2022: 549 shares worth $165K. The stake represents ﹤0.01% of the portfolio and ranks #1971 among its holdings.

156 funds tracked by Wall St. Rank hold KYNB as of Q1 2022.

Amalgamated Financial held 549 shares of Kyntra Bio worth $165K as of Q1 2022.
Kyntra Bio was a new Amalgamated Financial position in Q1 2022.
Kyntra Bio made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1971 holding.
156 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.